title: Managing anxiety and depression in alcohol and drug dependence.
abstract: Previous research has highlighted the high prevalence (30-60%) of comorbid anxiety and mood disorders in clients with substance misuse disorders and, equivalently, a third of those with affective disorder report a history of substance use disorder (Kessler et al., 1994; Regier et al., 1990; Robins & Regier, 1991). This article reviews the management of such cases and identifies key issues in the assessment process, as well as potential avenues for treatment. Other articles have highlighted the increased service utilisation and the cost of care and treatment of comorbidity. This article will primarily focus on the management of individual cases and will briefly refer to issues of service organisation. Although antidepressant or anxiolytic pharmacotherapy may have a role in the treatment of severe disorders, the benefits of using these medications must be balanced against the increased risk of side-effects or adverse reactions in individuals who continue to engage in substance misuse or who have medical complications associated with drug or alcohol dependency. Effective psychosocial approaches largely focus on brief, empirically tested manualised therapies such as cognitive therapy (Carroll, 1998a). However, modifications are required to such approaches to ensure that the interventions are tailored to the needs of clients exhibiting comorbidity. The data available demonstrate some evidence for the benefits of structured psychological approaches, but more sophisticated randomized controlled trials are required to evaluate the efficacy of both psychological and pharmacological approaches.
authors.affiliation: University Department of Psychiatry, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
authors.forename: J
authors.initials: J
authors.lastname: Scott
authors.forename: E
authors.initials: E
authors.lastname: Gilvarry
authors.forename: M
authors.initials: M
authors.lastname: Farrell
mesh_terms: D019973:Alcohol-Related Disorders / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D014151:Anti-Anxiety Agents / Q000592:standards / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000592:standards / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D002986:Clinical Trials as Topic; D003863:Depression / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D017831:Diagnosis, Dual (Psychiatry) / Q000379:methods; D006801:Humans; D011613:Psychotherapy / Q000379:methods / Q000592:standards; D019966:Substance-Related Disorders / Q000150:complications / Q000175:diagnosis / Q000628:therapy
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents